Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.7400
+0.0810 (12.29%)
At close: Aug 7, 2026, 4:00 PM EDT
0.7434
+0.0034 (0.46%)
After-hours: Aug 7, 2026, 7:43 PM EDT
Invivyd Revenue
Invivyd had revenue of $13.74M in the quarter ending March 31, 2026, with 21.59% growth. This brings the company's revenue in the last twelve months to $55.87M, up 52.27% year-over-year. In the year 2025, Invivyd had annual revenue of $53.43M with 110.47% growth.
Revenue (ttm)
$55.87M
Revenue Growth
+52.27%
P/S Ratio
3.90
Revenue / Employee
$457,918
Employees
122
Market Cap
218.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.43M | 28.04M | 110.47% |
| Dec 31, 2024 | 25.38M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 74.00M |
| Precision BioSciences | 45.06M |
| Atrium Therapeutics | 36.68M |
| Arcturus Therapeutics Holdings | 29.37M |
| Keros Therapeutics | 15.01M |
| Camp4 Therapeutics | 3.93M |
IVVD News
- 5 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Invivyd announces notice of termination for Pemgarda Emergency Use Authorization - TheFly
- 4 weeks ago - Invivyd Announces Receipt of Twelve Months' Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA - GlobeNewsWire
- 5 weeks ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer - GlobeNewsWire
- 7 weeks ago - Invivyd completes enrollment of LIBERTY clinical trial - TheFly
- 7 weeks ago - Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - GlobeNewsWire
- 2 months ago - Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration - GlobeNewsWire